Therapeutic Area / Stakeholder focus** **_(Subject to change as the Rare Diseases Business Unit evolves)_** The Senior Medical Science Liaison, Rare Diseases, supports highly specialized stakeholder groups that differ from traditional MSL customer profiles and may include, but are not limited to: + FUS ALS: Neurologists, neuromuscular specialists, ALS specialists and ALS centers, investigators, multidisciplinary care teams, and relevant advocacy organizations + PKU: Metabolic geneticists, inherited metabolic disease specialists, dietitians, specialized treatment centers and care teams, investigators, and relevant advocacy organizations This role engages stakeholders through a strategic, account-based approach, with a strong emphasis on Centers of Excellence and specialized referral or treatment centers. This field-based role engages highly specialized stakeholders-including key opinion leaders (KOLs), investigators, healthcare providers, advocacy organizations, and multidisciplinary care teams-to advance patient outcomes aligned with Otsuka's overarching objectives.